Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
9 pending office actions • 7 art units • 9 examiners • 0 of 9 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
The University of Sydney manages a portfolio with 9 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 9 distinct examiners, ensuring that every pending matter is reviewed by a different official. This level of examiner variety is accompanied by a technical reach that spans 7 distinct art units. The presence of 7 distinct art units suggests that the university's research output is evaluated by many different specialized divisions within the patent office. Practitioners must tailor their strategies to a wide variety of technical standards and examiner cultures across these 7 distinct art units.
LIPPERT, JOHN WILLIAM is the busiest examiner for the university, currently overseeing 1 pending office action. Given that there are 9 pending office actions and 9 distinct examiners, the workload is decentralized. This means that no single examiner's individual tendencies will dominate the university's overall prosecution. For practitioners, the involvement of 7 distinct art units indicates that prosecution strategies must be highly adaptable. The 9 pending actions represent a significant commitment to securing intellectual property in the biotechnology sector. This arrangement requires managing multiple examiner interactions across the various technical divisions identified in the data. The decentralized nature of the 9 pending office actions provides the university with a broad range of independent reviews for its pharmaceutical innovations.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 5 (56%) |
| §112 only | 1 (11%) |
| Multi-statute (no §101) | 3 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LIPPERT, JOHN WILLIAM | 1 | 58.2% | +40.0% |
| RODRIGUEZ-GARCIA, VALERIE | 1 | 68.9% | +31.8% |
| FELTON, AILEEN BAKER | 1 | 51.9% | +16.5% |
| COPPINS, JANET L | 1 | 72.6% | +26.1% |
| BAEK, JONGHWAN NMN | 1 | 60.0% | +0.0% |
| CONTRERAS, CIEL P | 1 | 54.3% | +33.6% |
| NIEBAUER, RONALD T | 1 | 40.8% | +34.0% |
| MARTIN, RACHEL E | 1 | 53.6% | +56.4% |
| REYNOLDS, FRED H | 1 | 33.0% | +39.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17616809 | ANTI-INFLAMMATORY AGENTS | NIEBAUER, RONALD T | 70d |
| 18453027 | VANADIUM COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | COPPINS, JANET L | — |
| 18248167 | PLASMA ASSISTED ELECTROCATALYTIC CONVERSION | CONTRERAS, CIEL P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17608463 | PEPTIDE DERIVATIVES AND CONJUGATES THEREOF FOR TREATING CANCER | REYNOLDS, FRED H | 85d overdue |
| 17594994 | METHODS FOR THE FRACTIONATION OF PROTEINS | MARTIN, RACHEL E | 1d overdue |
| 18441515 | ANTI-CANCER COMPOUNDS | RODRIGUEZ-GARCIA, VALERIE | 9d |
| 18532759 | CHEMICAL INHIBITORS FOR HIGH TEMPERATURE AND REACTIVE GROUND | FELTON, AILEEN BAKER | 36d |
| 17616809 | ANTI-INFLAMMATORY AGENTS | NIEBAUER, RONALD T | 70d |
| 18844576 | IN VIVO TRANSITION METAL DETECTION | LIPPERT, JOHN WILLIAM | — |
| 18453027 | VANADIUM COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | COPPINS, JANET L | — |
| 18248167 | PLASMA ASSISTED ELECTROCATALYTIC CONVERSION | CONTRERAS, CIEL P | — |
| Art Unit | Apps |
|---|---|
| 1658 | 2 |
| 1621 | 1 |
| 1734 | 1 |
| 1628 | 1 |
| 1618 | 1 |
| 1794 | 1 |
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18844576 | IN VIVO TRANSITION METAL DETECTION | LIPPERT, JOHN WILLIAM | — | §103 | Non-Final OA | — | Pending | Sep 06, 2024 |
| 18441515 | ANTI-CANCER COMPOUNDS | RODRIGUEZ-GARCIA, VALERIE | 1621 | §112 | Final Rejection | 9d | Pending | Feb 14, 2024 |
| 18532759 | CHEMICAL INHIBITORS FOR HIGH TEMPERATURE AND REACTIVE GROUND | FELTON, AILEEN BAKER | 1734 | §103 | Non-Final OA | 36d | Pending | Dec 07, 2023 |
| 18453027 | VANADIUM COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | COPPINS, JANET L | 1628 | §102§103§112 | Non-Final OA | — | Pending | Aug 21, 2023 |
| 18258394 | LIGANDS AND THEIR USE | BAEK, JONGHWAN NMN | 1618 | §103 | Final Rejection | — | Pending | Jun 20, 2023 |
| 18248167 | PLASMA ASSISTED ELECTROCATALYTIC CONVERSION | CONTRERAS, CIEL P | 1794 | §102§103§112 | Non-Final OA | — | Pending | Apr 06, 2023 |
| 17616809 | ANTI-INFLAMMATORY AGENTS | NIEBAUER, RONALD T | 1658 | §103§112 | Non-Final OA | 70d | Pending | Dec 06, 2021 |
| 17594994 | METHODS FOR THE FRACTIONATION OF PROTEINS | MARTIN, RACHEL E | 1657 | §103 | Final Rejection | 1d overdue | Pending | Nov 04, 2021 |
| 17608463 | PEPTIDE DERIVATIVES AND CONJUGATES THEREOF FOR TREATING CANCER | REYNOLDS, FRED H | 1658 | §103 | Non-Final OA | 85d overdue | Pending | Nov 02, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial